Diagnosis and Risk Stratification in Multiple Myeloma
- 22 July 2014
- journal article
- review article
- Published by Elsevier BV in Hematology/Oncology Clinics of North America
- Vol. 28 (5), 791-813
- https://doi.org/10.1016/j.hoc.2014.06.007
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal functionCancer, 2010
- Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and OutcomeClinical Cancer Research, 2010
- TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3British Journal of Haematology, 2009
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaBlood, 2009
- Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocolsBlood, 2009
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)Leukemia, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaThe New England Journal of Medicine, 2008
- The molecular classification of multiple myelomaBlood, 2006